The US Food and Drug Agency (FDA). approved this Saturday the emergency authorization of the Johnson & Johnson COVID-19 Vaccine (J&J), which requires a single injection, and will be the third to be available in the country.
The J&J vaccine will thus join those of Pfizer / BioNTech and Moderna, which have been administered since the end of December and which have served to immunize health, emergency and elderly personnel, and will help accelerate distribution to the rest of the population, whose first doses may be inoculated in the coming days.
“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method of COVID-19, to help us fight this pandemic, which has claimed the lives of half a million lives in the US, “said FDA Acting Director Janet Woodcok in the approval announcement statement.
Although in recent days the The average daily number of new cases in the US has declined markedlyThe authorities continue to warn of the existing danger, especially due to the appearance of new strains, down to below 70,000 a day, compared to nearly 300,000 at the beginning of the year.
“Now is not the time to relax restrictions. Although we have seen large reductions in cases and hospital admissions in the past six weeks, these declines come after the largest peak we’ve ever seen in the pandemic, “said Rochelle Walensky, director of the Centers for Disease Control and Prevention. CDC) at a press conference on Friday.
The tests with the J&J vaccine have shown a 66% effectiveness against coronavirus, below 94-95% of existing vaccines, but with an 86% ability to avoid severe cases of disease, hospitalizations and deaths.
U.S, the country hardest hit by the pandemic in the world, already registers more than 28.5 million cases and more than 510,000 deaths, according to the latest independent count of the Universidad Johns Hopkins.
Newsletter All about the coronavirus
The COVID-19 has put everyone on alert. Subscribe to our newsletter All about the coronavirus, where you will find the most relevant daily data in the country and the world on the progress of the virus and the fight against its spread.
– ‘Espacio Vital’: What should we know about the Novavax vaccine?